drugset
drugset / Trial / NCT05824390

A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy

NCT05824390 ↗

Phase 4 Unknown 116 enrolled XIEJINGYUAN Dongfang Hospital Affiliated to Tongji University · collabNingbo Municipal Yinzhou District No.2 Hospital · collabRuijin Hospital · collabShanghai Pudong New Area People's Hospital · collabSir Run Run Shaw Hospital · collabThird Affiliated Hospital, Sun Yat-Sen University · collabXiamen Humanity Hospital · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.

Timeline

Start
2020-06-20
Primary completion
2023-10-01
Completion
2023-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 1 g Intravenous

Indications

IgA glomerulonephritis